

NCCN Bone Cancer Guidelines V.1.2012 – Update Teleconference – 09/12/2011

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
BONE-C Internal request: Institutional Review comment requesting that ifosfamide and etoposide be deleted as a first-line therapy option for osteosarcoma.	Based on the data in the noted reference, the panel had included IE as an option for first-line therapy (primary/adjuvant/neoadjuvant) for newly diagnosed patients with osteosarcoma. During the recent update teleconference, the panel consensus was that it is not standard practice to use IE alone for first-line therapy for newly diagnosed patients with osteosarcoma.	Goorin AM, Harris MD, Bernstein M, et al. Phase II/III Trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. JCO 2002; 20(2):426-433.	12	0	0